Literature DB >> 9764547

Risk assessment and risk-based therapy in febrile neutropenic patients.

K V Rolston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9764547     DOI： 10.1007/bf01691127

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  14 in total

Review 1.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.

Authors:  W T Hughes; D Armstrong; G P Bodey; A E Brown; J E Edwards; R Feld; P Pizzo; K V Rolston; J L Shenep; L S Young
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

2.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

Review 3.  Controversies in the management of febrile neutropenic cancer patients.

Authors:  M Rubin; J W Hathorn; P A Pizzo
Journal:  Cancer Invest       Date:  1988       Impact factor: 2.176

4.  The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.

Authors:  J A Talcott; R Finberg; R J Mayer; L Goldman
Journal:  Arch Intern Med       Date:  1988-12

Review 5.  Management of fever in patients with cancer and treatment-induced neutropenia.

Authors:  P A Pizzo
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

Review 6.  American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

Authors: 
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

7.  Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.

Authors:  E B Rubenstein; K Rolston; R S Benjamin; J Loewy; C Escalante; E Manzullo; P Hughes; B Moreland; A Fender; K Kennedy
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

8.  A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.

Authors:  K V Rolston; P Berkey; G P Bodey; E J Anaissie; N M Khardori; J H Joshi; M J Keating; F A Holmes; F F Cabanillas; L Elting
Journal:  Arch Intern Med       Date:  1992-02

9.  Antibiotics in patients with neutropenia.

Authors:  G P Bodey
Journal:  Arch Intern Med       Date:  1984-09

Review 10.  Expanding the options for risk-based therapy in febrile neutropenia.

Authors:  K V Rolston
Journal:  Diagn Microbiol Infect Dis       Date:  1998-06       Impact factor: 2.803
View more
  1 in total

1.  Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials.

Authors:  H Imran; I M Tleyjeh; C A S Arndt; L M Baddour; P J Erwin; C Tsigrelis; N Kabbara; V M Montori
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-16       Impact factor: 3.267
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.